Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 16,542 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Connective Tissue Disease Clear all

Conditions: Actinic Keratosis
Interventions: 5-fluorouracil 5% cream, Calcipotriol 0.005% ointment, Vaseline; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions: Fulvestrant, Exemestane; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 32 Years to 91 Years · Female only
Enrollment: 694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 51
States / cities: Birmingham, Alabama • Arcadia, California • Fountain Valley, California + 48 more

Conditions: Psoriasis
Interventions: Topical Therapy, Phototherapy and Systemic Therapy, Biologic Therapy; Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Irvine, California

Conditions: HER-2 Positive Metastatic Breast Cancer
Interventions: Etoposide, Trastuzumab; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Immune Checkpoint Inhibitors, Metastatic Solid Tumor, Nonsmall Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Gastrointestinal Cancer, Squamous Cell Carcinoma
Interventions: Immunotherapy; Biological
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Tucson, Arizona • Albuquerque, New Mexico • Oklahoma City, Oklahoma + 3 more

Conditions: Vitiligo
Interventions: Ibuprofen; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 90 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Actinic Keratosis
Interventions: imiquimod cream, placebo cream; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • Saint Petersberg, Florida + 11 more

Conditions: Carpal Tunnel Syndrome, Trigger Finger, Ganglion Cysts, Distal Radius Fracture, Finger Fracture, De Quervain Syndrome
Interventions: Mobile App; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Sturge Weber Syndrome
Interventions: Everolimus; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 2 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Raynaud, Scleroderma
Interventions: Fasudil; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alopecia Areata
Interventions: Deuruxolitinib, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 54
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 44 more

Conditions: Rheumatoid Arthritis
Interventions: Tofacitinib, Abatacept; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 29,464 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Interventions: MORAb-066; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Nashville, Tennessee

Conditions: Obesity, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: Dietary Intervention, Educational Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment; Dietary Supplement · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Duarte, California

Conditions: Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Ovarian Adenocarcinoma, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Non Small Cell Lung Cancer
Interventions: TC-510, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: TCR2 Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: San Franciso, California • Miami, Florida • Bethesda, Maryland + 4 more

Conditions: Breast Carcinoma, Breast Neoplasm
Interventions: Ultrasound; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
Interventions: Elacestrant, Abemaciclib; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 11
States / cities: Fullerton, California • Los Angeles, California • Urbana, Illinois + 8 more

Conditions: Breast Cancer, Alopecia
Interventions: PAXMAN Orbis Scalp Cooler, Control No treatment; Device · Other
Lead sponsor: Julie Nangia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 7
States / cities: Morristown, New Jersey • New York, New York • Cleveland, Ohio + 2 more

Conditions: Diabetic Foot Ulcer
Interventions: CARE-D-Foot-Nav, Standard of care; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Imipramine, Photodynamic Therapy, Actinic Keratosis
Interventions: Imipramine, Vehicle; Drug · Other
Lead sponsor: Wright State University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Fairborn, Ohio

Conditions: Breast Cancer, Lung Cancer, Genito Urinary Cancer
Interventions: End-of-life conversation game called "Hello"; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions: Observational; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years to 100 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more

Conditions: Brain Cancer, Thyroid Cancer, Circulatory Disease, Breast Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Breast Cancer
Interventions: bendamustine, erlotinib, Maintenance erlotinib; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Actinic Keratosis Study

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

Evaluation of Vitamin D Levels in Psoriasis Patients

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Effect of Combination Non Steroidal Antiinflammatory Drugs and Narrowband UVB Treatment in Non-Photoadapters

Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery

Alternatives to Hand Therapy for Hand Surgery Patients

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tofacitinib vs Abatacept

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Scalp Cooling to Prevent Chemo-induced Hair Loss

Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation

The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning

Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study

Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer